A CHK1-inhibitor conjugate carries a drug that interferes with a replication-stress checkpoint. A published conference abstract reports a HER2-directed preclinical example.
CHK1 inhibition is the cargo mechanism only when the inhibitor is physically attached to the conjugate. The AACR 2026 abstract describes engineered-cysteine trastuzumab, a cleavable linker and a CHK1-inhibitor payload. The investigators tested cells and a HER2-positive breast-cancer xenograft model. This establishes a publicly described payload design and model experiment, separate from giving an oral checkpoint inhibitor alongside another ADC. It does not establish human safety, benefit after a TOP1 ADC or a treatment-selection rule.
In plain words · CHEK1 (Serine/threonine-protein kinase Chk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Small-cell lung cancer.
Showing the target this term concerns: CHEK1.
Shares ADC analytes and exposure, Synthetic lethality, Antibody-drug conjugate (ADC).
Shares ADC analytes and exposure, Antibody-drug conjugate (ADC).
Shares CHEK1, DNA replication stress, Synthetic lethality.
Shares ADC analytes and exposure, Antibody-drug conjugate (ADC).
Shares DNA replication stress, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/